Received Apr 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | — | — |
some swelling; Pain; This spontaneous report was received from field-based employee (FBE) and refers to a female patient of unknown age. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient was vaccinated with a dose of Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (strength, dose, dose number, route, anatomical location, lot # and expiration date were not reported) for prophylaxis. On an unknown date, the patient experienced some swelling and pain. The primary reporter could not confirm if swelling and pain started before or after patient was administered Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE). The patient went to a hospital to seek treatment for pain and swelling about one week ago and unknown if patient was admitted. At the reporting time, the outcome of some swelling and Pain was unknown. The causal relationship between both events and Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) was unknown.